Sibling and unrelated allogeneic hematopoietic stem cell transplantation for multiple myeloma patients under 45-year-old at early stage

Wenjian MO; Qingshan LI; Shunqing Wang; Ming Zhou; Wei Zhou; Xiaowei Chen; Shilin XU

Return

Sibling and unrelated allogeneic hematopoietic stem cell transplantation for multiple myeloma patients under 45-year-old at early stage

VernacularTitle:早期进行同胞及非亲缘异基因造血干细胞移植治疗45岁以下多发性骨髓瘤
Author: Wenjian MO ; Qingshan LI ; Shunqing WANG ; Ming ZHOU ; Wei ZHOU ; Xiaowei CHEN ; Shilin XU
Publication Type:Journal Article
Keywords: Multiple myeloma; Sibling; Unrelated; Allogeneic hematopoietic stem cell transplantation; Under 45-year-old; Early stage
From: Journal of Leukemia & Lymphoma 2010;19(7):391-393,397
CountryChina
Language:Chinese
Abstract: Objective To evaluate the effectiveness and side effects in sibling and unrelated HLA identical allogeneic hematopoietic stem cell transplantation for multiple myeloma patients under 45-year-old at early stage. Methods Three patients with multiple myeloma ranged from 38 to 44-year-old received two courses of chemotherapies and achieved partial remission. Sibling HLA identical allogeneic hematopoietic stem cell transplantations were underwent in case 1 and 2, and unrelated were in case 3. The conditioning regimens for case 1 and 2 included fludarabine, busulfan plus cyclophosphamide, and of case 3 included modified busulfan, cyclophosphamide plus antithymocyte globulin. Cycloporine A combined with methotrexate were used to prevent GVHD in the case 1 and 2, and methotrexate, mycophenolate and cycloporine A were used in case 3. Results All patients achieved full donor chimerism without graft failure. Grade Ⅱ acute GVHD and extensive chronic GVHD were found in case 1, but not in case 2 and 3. The period of follow-up of case 1, 2 and 3 were 48, 27 and 6 months, respectively, and all of them were alive with no signs of relapse. Conclusion The multiple myeloma patients under 45-year-old underwent sibling and unrelated HLA identical allogeneic hematopoietic stem cell transplantation at early stage after chemotherapy remission have the low treatment-related mortality, high complete remission rate and may prolong long-term survival.